{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:09:43Z","timestamp":1792807783452,"version":"4.5.0"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian J Gastroenterol"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s12664-023-01507-9","type":"journal-article","created":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T18:02:36Z","timestamp":1707760956000},"page":"22-35","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Tofacitinib use in ulcerative colitis: An expert consensus for day-to-day clinical practice"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3753-4933","authenticated-orcid":false,"given":"Rupa","family":"Banerjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishal","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajendra","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuraag","family":"Jena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Partha","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nalini","family":"Raghunathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajit","family":"Sood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amarender S.","family":"Puri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhabhadev","family":"Goswami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devendra","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhanush","family":"Mekala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. N.","family":"Ramesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. V.","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran","family":"Peddi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew","family":"Philip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manu","family":"Tandon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shobna","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubhankar","family":"Godbole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumit","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uday C.","family":"Ghoshal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usha","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vandana","family":"Midha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V. G. Mohan","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Nageshwar","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,12]]},"reference":[{"key":"1507_CR1","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1111\/j.1572-0241.2008.02158.x","volume":"103","author":"KT Thia","year":"2008","unstructured":"Thia KT, Loftus EV, Sandborn WJ, Yang SK. An update on the epidemiology of inflammatory bowel disease in Asia. Am J Gastroenterol. 2008;103:3167\u201382.","journal-title":"Am J Gastroenterol"},{"key":"1507_CR2","doi-asserted-by":"publisher","first-page":"637","DOI":"10.3390\/ph14070637","volume":"14","author":"I Ben Ghezala","year":"2021","unstructured":"Ben Ghezala I, Charkaoui M, Michiels C, Bardou M, Luu M. Small molecule drugs in inflammatory bowel diseases. Pharmaceuticals. 2021;14:637.","journal-title":"Pharmaceuticals"},{"key":"1507_CR3","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s40259-013-0040-7","volume":"27","author":"Y Furumoto","year":"2013","unstructured":"Furumoto Y, Gadina M. The arrival of jak inhibitors: advancing the treatment of immune and hematologic disorders. BioDrugs. 2013;27:431\u20138.","journal-title":"BioDrugs"},{"key":"1507_CR4","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41584-021-00726-8","volume":"18","author":"Y Tanaka","year":"2022","unstructured":"Tanaka Y, Luo Y, O\u2019Shea JJ, Nakayamada S. Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach. Nat Rev Rheumatol. 2022;18:133\u201345.","journal-title":"Nat Rev Rheumatol"},{"key":"1507_CR5","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1002\/jgh3.12362","volume":"4","author":"KL Ling","year":"2020","unstructured":"Ling KL, Hilmi I, Raja Ali RA, et al. Asian Pacific Association of Gastroenterology (APAGE) Inflammatory Bowel Disease (IBD) Working Party guidelines on IBD management during the COVID-19 pandemic. JGH Open. 2020;4:320\u20133. https:\/\/doi.org\/10.1002\/jgh3.12362.","journal-title":"JGH Open"},{"key":"1507_CR6","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1093\/ibd\/izaa202","volume":"27","author":"CN Bernstein","year":"2021","unstructured":"Bernstein CN, Ng SC, Banerjee R, et al. Worldwide management of inflammatory bowel disease during the COVID-19 pandemic: an international survey. Inflamm Bowel Dis. 2021;27:836\u201347.","journal-title":"Inflamm Bowel Dis"},{"key":"1507_CR7","doi-asserted-by":"publisher","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","volume":"68","author":"CA Lamb","year":"2019","unstructured":"Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68:s1\u2013106.","journal-title":"Gut."},{"key":"1507_CR8","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1053\/j.gastro.2020.03.012","volume":"158","author":"JD Feuerstein","year":"2020","unstructured":"Feuerstein JD, Isaacs KL, Schneider Y, et al. Spotlight: management of moderate-to-severe ulcerative colitis. Gastroenterology. 2020;158:1464.","journal-title":"Gastroenterology"},{"key":"1507_CR9","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/ecco-jcc\/jjab109","volume":"16","author":"R Gilmore","year":"2022","unstructured":"Gilmore R, Hilley P, Srinivasan A, Choy M, De Cruz P. Sequential use of high-dose tofacitinib after infliximab salvage therapy in acute severe ulcerative colitis. J Crohns Colitis. 2022;16:166\u20138.","journal-title":"J Crohns Colitis"},{"key":"1507_CR10","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1159\/000514781","volume":"29","author":"S Santos","year":"2022","unstructured":"Santos S, Gamelas V, Saraiva R, Sim\u00f5es G, Saiote J, Ramos J. Tofacitinib: an option for acute severe ulcerative colitis? GE Port J Gastroenterol. 2022;29:132\u20134.","journal-title":"GE Port J Gastroenterol"},{"key":"1507_CR11","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.cgh.2018.10.047","volume":"17","author":"B Kochar","year":"2019","unstructured":"Kochar B, Herfarth N, Mamie C, Navarini AA, Scharl M, Herfarth HH. Tofacitinib for the treatment of pyoderma gangrenosum. Clin Gastroenterol Hepatol. 2019;17:991\u20133.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1507_CR12","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","volume":"376","author":"WJ Sandborn","year":"2017","unstructured":"Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376:1723\u201336.","journal-title":"N Engl J Med"},{"key":"1507_CR13","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1016\/j.cgh.2020.10.038","volume":"20","author":"WJ Sandborn","year":"2022","unstructured":"Sandborn WJ, Peyrin-Biroulet L, Quirk D, et al. Efficacy and safety of extended induction with tofacitinib for the treatment of ulcerative colitis. Clin Gastroenterol Hepatol. 2022;20:1821-30.e3.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"1507_CR14","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.cgh.2018.07.009","volume":"17","author":"S Hanauer","year":"2019","unstructured":"Hanauer S, Panaccione R, Danese S, et al. Tofacitinib induction therapy reduces symptoms within 3 days for patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2019;17:139\u201347.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1507_CR15","doi-asserted-by":"publisher","first-page":"e323","DOI":"10.1097\/MCG.0000000000001608","volume":"56","author":"V Taneja","year":"2022","unstructured":"Taneja V, El-Dallal M, Haq Z, et al. Effectiveness and safety of tofacitinib for ulcerative colitis: systematic review and meta-analysis. J Clin Gastroenterol. 2022;56:e323\u201333.","journal-title":"J Clin Gastroenterol"},{"key":"1507_CR16","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1093\/ecco-jcc\/jjab065","volume":"15","author":"J Pan\u00e9s","year":"2021","unstructured":"Pan\u00e9s J, Vermeire S, Dubinsky MC, et al. Efficacy and safety of tofacitinib re-treatment for ulcerative colitis after treatment interruption: results from the OCTAVE clinical trials. J Crohns Colitis. 2021;15:1852\u201363.","journal-title":"J Crohns Colitis."},{"key":"1507_CR17","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/apt.15555","volume":"51","author":"BE Sands","year":"2020","unstructured":"Sands BE, Armuzzi A, Marshall JK, et al. Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open. Aliment Pharmacol Ther. 2020;51:271\u201380.","journal-title":"Aliment Pharmacol Ther"},{"key":"1507_CR18","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1056\/NEJMoa1112168","volume":"367","author":"WJ Sandborn","year":"2012","unstructured":"Sandborn WJ, Ghosh S, Panes J, et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med. 2012;367:616\u201324.","journal-title":"N Engl J Med"},{"key":"1507_CR19","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/apt.16712","volume":"55","author":"WJ Sandborn","year":"2022","unstructured":"Sandborn WJ, Lawendy N, Danese S, et al. Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment. Aliment Pharmacol Ther. 2022;55:464\u201378.","journal-title":"Aliment Pharmacol Ther"},{"key":"1507_CR20","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.cgh.2020.10.004","volume":"20","author":"JF Colombel","year":"2022","unstructured":"Colombel JF, Osterman MT, Thorpe AJ, et al. Maintenance of remission with tofacitinib therapy in patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2022;20:116-25.e5.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1507_CR21","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1093\/ecco-jcc\/jjaa249","volume":"15","author":"S Vermeire","year":"2021","unstructured":"Vermeire S, Su C, Lawendy N, et al. Outcomes of tofacitinib dose reduction in patients with ulcerative colitis in stable remission from the randomised RIVETING Trial. J Crohns Colitis. 2021;15:1130\u201341.","journal-title":"J Crohns Colitis"},{"key":"1507_CR22","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1111\/apt.15689","volume":"51","author":"VBC Biemans","year":"2020","unstructured":"Biemans VBC, Sleutjes JAM, de Vries AC, et al. Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry. Aliment Pharmacol Ther. 2020;51:880\u20138.","journal-title":"Aliment Pharmacol Ther"},{"key":"1507_CR23","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1093\/ibd\/izaa157","volume":"26","author":"S Honap","year":"2020","unstructured":"Honap S, Pavlidis P, Ray S, et al. Tofacitinib in acute severe ulcerative colitis-a real-world tertiary center experience. Inflamm Bowel Dis. 2020;26:e147\u20139.","journal-title":"Inflamm Bowel Dis"},{"key":"1507_CR24","doi-asserted-by":"publisher","first-page":"S274","DOI":"10.1093\/ecco-jcc\/jjy222.468","volume":"13","author":"R Ungaro","year":"2019","unstructured":"Ungaro R, Fenster M, Dimopoulos C, et al. P344 Real-world effectiveness of tofacitinib in ulcerative colitis: a multi-centre study. J Crohns Colitis. 2019;13:S274\u20135.","journal-title":"J Crohns Colitis"},{"key":"1507_CR25","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1093\/ecco-jcc\/jjaa145","volume":"15","author":"M Chaparro","year":"2021","unstructured":"Chaparro M, Garre A, Mesonero F, et al. Tofacitinib in ulcerative colitis: real-world evidence from the ENEIDA registry. J Crohns Colitis. 2021;15:35\u201342.","journal-title":"J Crohns Colitis"},{"key":"1507_CR26","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1093\/ibd\/izab011","volume":"28","author":"C Taxonera","year":"2022","unstructured":"Taxonera C, Olivares D, Alba C. Real-world effectiveness and safety of tofacitinib in patients with ulcerative colitis: systematic review with meta-analysis. Inflamm Bowel Dis. 2022;28:32\u201340.","journal-title":"Inflamm Bowel Dis."},{"key":"1507_CR27","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.dld.2021.11.009","volume":"54","author":"I Avni-Biron","year":"2022","unstructured":"Avni-Biron I, Bar-Gil Shitrit A, Koslowsky B, et al. Short-term effectiveness and safety of tofacitinib in ulcerative colitis - real world data from tertiary medical centers in Israel: tofacitinib in ulcerative colitis. Dig Liver Dis. 2022;54:192\u20137.","journal-title":"Dig Liver Dis"},{"key":"1507_CR28","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1093\/ibd\/izac121","volume":"29","author":"MD Long","year":"2023","unstructured":"Long MD, Afzali A, Fischer M, et al. Tofacitinib response in ulcerative colitis (TOUR): early response after initiation of tofacitinib therapy in a real-world setting. Inflamm Bowel Dis. 2023;29:570\u20138.","journal-title":"Inflamm Bowel Dis"},{"key":"1507_CR29","doi-asserted-by":"publisher","first-page":"S755","DOI":"10.1093\/ecco-jcc\/jjaa017","volume":"14","author":"M Agrawal","year":"2020","unstructured":"Agrawal M, Kim ES, Colombel JF. Jak inhibitors safety in ulcerative colitis: practical implications. J Crohns Colitis. 2020;14:S755\u201360.","journal-title":"J Crohns Colitis"},{"key":"1507_CR30","first-page":"e4541","volume":"15","author":"S Malakar","year":"2023","unstructured":"Malakar S, Kothalkar S, Hoda US, Ghoshal UC. Tofacitinib in steroid-refractory acute severe ulcerative colitis: a retrospective analysis. Cureus. 2023;15:e4541.","journal-title":"Cureus."},{"key":"1507_CR31","doi-asserted-by":"publisher","first-page":"e101","DOI":"10.1093\/ibd\/izab087","volume":"27","author":"A Jena","year":"2021","unstructured":"Jena A, Mishra S, Sachan A, Singh H, Singh AK, Sharma V. Tofacitinib in acute severe ulcerative colitis: case series and a systematic review. Inflamm Bowel Dis. 2021;27:e101\u20133.","journal-title":"Inflamm. Bowel Dis"},{"key":"1507_CR32","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/j.dld.2023.05.021","volume":"55","author":"K Mpakogiannis","year":"2023","unstructured":"Mpakogiannis K, Fousekis FS, Christodoulou DK, Katsanos KH, Narula N. The current role of tofacitinib in acute severe ulcerative colitis in adult patients: a systematic review. Dig Liver Dis. 2023;55:1311\u20137.","journal-title":"Dig Liver Dis"},{"key":"1507_CR33","doi-asserted-by":"publisher","first-page":"e615","DOI":"10.14309\/01.ajg.0000860044.17638.e9","volume":"117","author":"MK Goyal","year":"2022","unstructured":"Goyal MK, Midha V, Mehta V, et al. S851 Role of tofacitinib as an adjunct to intravenous corticosteroids in the management of acute severe ulcerative colitis: an interim analysis. Am J Gastroenterol. 2022;117:e615.","journal-title":"Am J Gastroenterol"},{"key":"1507_CR34","unstructured":"Kedia S. Dual therapy with tofacitinib and corticosteroids versus corticosteroids for treatment of acute severe ulcerative colitis: a parallel, double blind, placebo-controlled, randomized trial\u00a0[CTRI\/2022\/11\/047186, registered on 10-11-2022]."},{"key":"1507_CR35","doi-asserted-by":"publisher","first-page":"175628482110057","DOI":"10.1177\/17562848211005708","volume":"14","author":"DT Rubin","year":"2021","unstructured":"Rubin DT, Reinisch W, Greuter T, et al. Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis. Therap Adv Gastroenterol. 2021;14:175628482110057.","journal-title":"Therap Adv Gastroenterol"},{"key":"1507_CR36","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40259-019-00333-w","volume":"33","author":"AT Virtanen","year":"2019","unstructured":"Virtanen AT, Haikarainen T, Raivola J, Silvennoinen O. Selective JAKinibs: prospects in inflammatory and autoimmune diseases. BioDrugs. 2019;33:15\u201332.","journal-title":"BioDrugs"},{"key":"1507_CR37","doi-asserted-by":"publisher","first-page":"7140","DOI":"10.1038\/s41598-022-10777-w","volume":"12","author":"L Hoisnard","year":"2022","unstructured":"Hoisnard L, Lebrun-Vignes B, Maury S, et al. Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database. Sci Rep. 2022;12:7140.","journal-title":"Sci Rep"},{"key":"1507_CR38","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1080\/17474124.2022.2106216","volume":"16","author":"S Mishra","year":"2022","unstructured":"Mishra S, Jena A, Kakadiya R, Sharma V, Ahuja V. Positioning of tofacitinib in treatment of ulcerative colitis: a global perspective. Expert Rev Gastroenterol Hepatol. 2022;16:737\u201352.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"1507_CR39","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1016\/j.cgh.2020.06.050","volume":"19","author":"P Deepak","year":"2021","unstructured":"Deepak P, Alayo QA, Khatiwada A, et al. Safety of tofacitinib in a real-world cohort of patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2021;19:1592-601.e3.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1507_CR40","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1093\/ibd\/izaa289","volume":"27","author":"JR Curtis","year":"2021","unstructured":"Curtis JR, Regueiro M, Yun H, et al. Tofacitinib treatment safety in moderate to severe ulcerative colitis: comparison of observational population cohort data from the IBM MarketScan\u00ae administrative claims database with tofacitinib trial data. Inflamm Bowel Dis. 2021;27:1394\u2013408.","journal-title":"Inflamm Bowel Dis"},{"key":"1507_CR41","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386:316\u201326.","journal-title":"N Engl J Med"},{"key":"1507_CR42","unstructured":"FDA Drug Safety Communication. Safety trial finds risk of blood clots in the lungs and death with higher dose of tofacitinib (Xeljanz, Xeljanz XR) in rheumatoid arthritis patients [Internet]. 2019. Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/safety-trial-finds-risk-blood-clots-lungs-and-death-higher-dose-tofacitinib-xeljanz-xeljanz-xr."},{"key":"1507_CR43","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/j.cgh.2018.11.035","volume":"17","author":"WJ Sandborn","year":"2019","unstructured":"Sandborn WJ, Pan\u00e9s J, D\u2019Haens GR, et al. Safety of tofacitinib for treatment of ulcerative colitis, based on 4.4 years of data from global clinical trials. Clin Gastroenterol Hepatol. 2019;17:1541\u201350.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"1507_CR44","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1055\/s-0037-1615600","volume":"85","author":"CN Bernstein","year":"2001","unstructured":"Bernstein CN, Blanchard JF, Houston DS, Wajda A. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thromb Haemost. 2001;85:430\u20134.","journal-title":"Thromb Haemost."},{"key":"1507_CR45","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1136\/gut.2010.228585","volume":"60","author":"MD Kappelman","year":"2011","unstructured":"Kappelman MD, Horvath-Puho E, Sandler RS, et al. Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study. Gut. 2011;60:937\u201343.","journal-title":"Gut."},{"key":"1507_CR46","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1093\/ecco-jcc\/jjaa233","volume":"15","author":"KL Winthrop","year":"2021","unstructured":"Winthrop KL, Loftus EV, Baumgart DC, et al. Tofacitinib for the treatment of ulcerative colitis: analysis of infection rates from the ulcerative colitis clinical programme. J Crohns Colitis. 2021;15:914\u201329.","journal-title":"J Crohns Colitis."},{"key":"1507_CR47","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1186\/s13075-015-0880-2","volume":"17","author":"V Strand","year":"2015","unstructured":"Strand V, Ahadieh S, French J, et al. Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials. Arthritis Res Ther. 2015;17:362.","journal-title":"Arthritis Res Ther"},{"key":"1507_CR48","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1002\/art.39670","volume":"68","author":"H Yun","year":"2016","unstructured":"Yun H, Yang S, Chen L, et al. Risk of herpes zoster in autoimmune and inflammatory diseases: implications for vaccination. Arthritis Rheumatol. 2016;68:2328\u201337.","journal-title":"Arthritis Rheumatol"},{"key":"1507_CR49","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1016\/j.cgh.2006.09.019","volume":"4","author":"G Gupta","year":"2006","unstructured":"Gupta G, Lautenbach E, Lewis JD. Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006;4:1483\u201390.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"1507_CR50","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1016\/j.cgh.2017.12.052","volume":"16","author":"N Khan","year":"2018","unstructured":"Khan N, Patel D, Trivedi C, et al. Overall and comparative risk of herpes zoster with pharmacotherapy for inflammatory bowel diseases: a nationwide cohort study. Clin Gastroenterol Hepatol. 2018;16:1919-27.e3.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1507_CR51","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1093\/ibd\/izy311","volume":"25","author":"J C\u00f4t\u00e9-Daigneault","year":"2019","unstructured":"C\u00f4t\u00e9-Daigneault J, Bessissow T, Nicolae MV, et al. Herpes zoster incidence in inflammatory bowel disease patients: a population-based study. Inflamm Bowel Dis. 2019;25:914\u20138.","journal-title":"Inflamm Bowel Dis"},{"key":"1507_CR52","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.crohns.2013.12.013","volume":"8","author":"JF Rahier","year":"2014","unstructured":"Rahier JF, Magro F, Abreu C, et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2014;8:443\u201368.","journal-title":"J Crohns Colitis"},{"key":"1507_CR53","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1053\/j.gastro.2020.01.001","volume":"158","author":"PA Olivera","year":"2020","unstructured":"Olivera PA, Lasa JS, Bonovas S, Danese S, Peyrin-Biroulet L. Safety of Janus kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: a systematic review and meta-analysis. Gastroenterology. 2020;158:1554-73.e12.","journal-title":"Gastroenterology."},{"key":"1507_CR54","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1093\/ibd\/izy131","volume":"24","author":"KL Winthrop","year":"2018","unstructured":"Winthrop KL, Melmed GY, Vermeire S, et al. Herpes zoster infection in patients with ulcerative colitis receiving tofacitinib. Inflamm Bowel Dis. 2018;24:2258\u201365.","journal-title":"Inflamm Bowel Dis"},{"key":"1507_CR55","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1002\/art.40189","volume":"69","author":"KL Winthrop","year":"2017","unstructured":"Winthrop KL, Curtis JR, Lindsey S, et al. Herpes zoster and tofacitinib: clinical outcomes and the risk of concomitant therapy. Arthritis Rheumatol. 2017;69:1960\u20138.","journal-title":"Arthritis Rheumatol."},{"key":"1507_CR56","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1093\/ibd\/izac063","volume":"29","author":"KL Winthrop","year":"2023","unstructured":"Winthrop KL, Vermeire S, Long MD, et al. Long-term risk of herpes zoster infection in patients with ulcerative colitis receiving tofacitinib. Inflamm Bowel Dis. 2023;29:85\u201396.","journal-title":"Inflamm Bowel Dis"},{"key":"1507_CR57","doi-asserted-by":"publisher","first-page":"103","DOI":"10.15585\/mmwr.mm6703a5","volume":"67","author":"KL Dooling","year":"2018","unstructured":"Dooling KL, Guo A, Patel M, et al. Recommendations of the advisory committee on immunization practices for use of herpes zoster vaccines. MMWR Morb Mortal Wkly Rep. 2018;67:103\u20138.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1507_CR58","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s40266-018-0603-x","volume":"35","author":"YY Syed","year":"2018","unstructured":"Syed YY. Recombinant zoster vaccine (Shingrix\u00ae): a review in herpes zoster. Drugs Aging. 2018;35:1031\u201340.","journal-title":"Drugs Aging."},{"key":"1507_CR59","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/ajg.2016.537","volume":"112","author":"FA Farraye","year":"2017","unstructured":"Farraye FA, Melmed GY, Lichtenstein GR, Kane SV. ACG clinical guideline: preventive care in inflammatory bowel disease. Am J Gastroenterol. 2017;112:241\u201358.","journal-title":"Am J Gastroenterol."},{"key":"1507_CR60","unstructured":"Harpaz R, Ortega-Sanchez IR, Seward JF; Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008;57(RR-5):1-CE4."},{"key":"1507_CR61","first-page":"1872","volume":"53","author":"A Souto","year":"2014","unstructured":"Souto A, Maneiro JR, Salgado E, Carmona L, Gomez-Reino JJ. Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies. Rheumatol (United Kingdom). 2014;53:1872\u201385.","journal-title":"Rheumatol (United Kingdom)"},{"key":"1507_CR62","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1136\/annrheumdis-2015-207319","volume":"75","author":"KL Winthrop","year":"2016","unstructured":"Winthrop KL, Park SH, Gul A, et al. Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75:133\u20131138. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207319.","journal-title":"Ann Rheum Dis"},{"key":"1507_CR63","doi-asserted-by":"publisher","first-page":"e001395","DOI":"10.1136\/rmdopen-2020-001395","volume":"6","author":"SB Cohen","year":"2020","unstructured":"Cohen SB, Tanaka Y, Mariette X, et al. Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme. RMD Open. 2020;6:e001395. https:\/\/doi.org\/10.1136\/rmdopen-2020-001395.","journal-title":"RMD Open"},{"key":"1507_CR64","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1111\/1756-185X.13853","volume":"23","author":"A Chopra","year":"2020","unstructured":"Chopra A, Shobha V, Chandrashekara S, et al. Tofacitinib in the treatment of Indian patients with rheumatoid arthritis: a post hoc analysis of efficacy and safety in phase 3 and long-term extension studies over 7 years. Int J Rheum Dis. 2020;23:882\u201397. https:\/\/doi.org\/10.1111\/1756-185X.13853.","journal-title":"Int J Rheum Dis"},{"key":"1507_CR65","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1093\/infdis\/jis269","volume":"205","author":"M Maiga","year":"2012","unstructured":"Maiga M, Lun S, Guo H, Winglee K, Ammerman NC, Bishai WR. Risk of tuberculosis reactivation with tofacitinib (CP-690550). J Infect Dis. 2012;205:1705\u20138. https:\/\/doi.org\/10.1093\/infdis\/jis269.","journal-title":"J Infect Dis"},{"key":"1507_CR66","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1097\/CM9.0000000000001948","volume":"135","author":"X Ji","year":"2022","unstructured":"Ji X, Hu L, Wang Y, et al. Risk of tuberculosis in patients with rheumatoid arthritis treated with biological and targeted drugs: meta-analysis of randomized clinical trials. Chin Med J (Engl). 2022;135:409\u201315. https:\/\/doi.org\/10.1097\/CM9.0000000000001948.","journal-title":"Chin Med J (Engl)"},{"key":"1507_CR67","doi-asserted-by":"publisher","first-page":"e24","DOI":"10.1093\/ibd\/izab234","volume":"28","author":"S Mishra","year":"2022","unstructured":"Mishra S, Kumar Singh A, Kopp C, Jena A, Sharma V. Tubercular pleural effusion in a patient of ulcerative colitis treated with tofacitinib. Inflamm Bowel Dis. 2022;28:e24. https:\/\/doi.org\/10.1093\/ibd\/izab234.","journal-title":"Inflamm Bowel Dis"},{"key":"1507_CR68","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1093\/ecco-jcc\/jjab200","volume":"16","author":"F Charpy","year":"2022","unstructured":"Charpy F, Altwegg R, Debourdeau A. Disseminated tuberculosis in a patient treated with tofacitinib for ulcerative colitis. J Crohns Colitis. 2022;16:685\u20136. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjab200.","journal-title":"J Crohns Colitis"},{"key":"1507_CR69","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1111\/apt.16839","volume":"55","author":"P Kumar","year":"2022","unstructured":"Kumar P, Vuyyuru SK, Kante B, et al. Stringent screening strategy significantly reduces reactivation rates of tuberculosis in patients with inflammatory bowel disease on anti-TNF therapy in tuberculosis endemic region. Aliment Pharmacol Ther. 2022;55:1431\u201340. https:\/\/doi.org\/10.1111\/apt.16839.","journal-title":"Aliment Pharmacol Ther"},{"key":"1507_CR70","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.jbspin.2020.04.010","volume":"87","author":"SH Nam","year":"2020","unstructured":"Nam SH, Oh JS, Hong S, et al. Early discontinuation of tofacitinib in patients with rheumatoid arthritis co-treated with rifampin for latent tuberculosis. Jt Bone Spine. 2020;87:475\u20139. https:\/\/doi.org\/10.1016\/j.jbspin.2020.04.010.","journal-title":"Jt Bone Spine"},{"key":"1507_CR71","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/apt.16952","volume":"56","author":"SR Fehily","year":"2022","unstructured":"Fehily SR, Al-Ani AH, Abdelmalak J, et al. Review article: latent tuberculosis in patients with inflammatory bowel diseases receiving immunosuppression\u2014risks, screening, diagnosis and management. Aliment Pharmacol Ther. 2022;56:6\u201327. https:\/\/doi.org\/10.1111\/apt.16952.","journal-title":"Aliment Pharmacol Ther"},{"key":"1507_CR72","doi-asserted-by":"publisher","unstructured":"Viola A, Li Voti R, Bivacqua C, et al. Mitigating the risk of tofacitinib-induced adverse events in the elderly population with Ulcerative Colitis. J Crohns Colitis. 2023. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjad158.","DOI":"10.1093\/ecco-jcc\/jjad158"},{"key":"1507_CR73","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/ibd\/izac084","volume":"29","author":"GR Lichtenstein","year":"2023","unstructured":"Lichtenstein GR, Bressler B, Francisconi C, et al. Assessment of safety and efficacy of tofacitinib, stratified by age, in patients from the ulcerative colitis clinical program. Inflamm Bowel Dis. 2023;29:27\u201341.","journal-title":"Inflamm Bowel Dis"},{"key":"1507_CR74","doi-asserted-by":"publisher","first-page":"e57","DOI":"10.1097\/MPG.0000000000003190","volume":"73","author":"H Moore","year":"2021","unstructured":"Moore H, Dubes L, Fusillo S, Baldassano R, Stein R. Tofacitinib therapy in children and young adults with pediatric-onset medically refractory inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2021;73:e57\u201362.","journal-title":"J Pediatr Gastroenterol Nutr."},{"key":"1507_CR75","doi-asserted-by":"publisher","first-page":"e332","DOI":"10.1097\/PG9.0000000000000332","volume":"4","author":"N Ryan","year":"2023","unstructured":"Ryan N, Cooper S, Dominik A, et al. Outcomes of tofacitinib use in an Irish Pediatric Cohort. JPGN Reports. 2023;4:e332.","journal-title":"JPGN Reports"},{"key":"1507_CR76","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1097\/MPG.0000000000003616","volume":"75","author":"BD Constant","year":"2022","unstructured":"Constant BD, Baldassano R, Kirsch J, Mitchel EB, Stein R, Albenberg L. Tofacitinib salvage therapy for children hospitalized for corticosteroid-and biologic-refractory ulcerative colitis. J Pediatr Gastroenterol Nutr. 2022;75:724\u201330.","journal-title":"J Pediatr Gastroenterol Nutr."},{"key":"1507_CR77","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.gastrohep.2022.10.020","volume":"46","author":"V Parra-Izquierdo","year":"2023","unstructured":"Parra-Izquierdo V, Fr\u00edas-Ordo\u00f1ez JS, M\u00e1rquez JR, et al. Tofacitinib in the treatment of moderate to severe ulcerative colitis in Colombia: real world experience. Gastroenterol Hepatol. 2023;46:512\u201321.","journal-title":"Gastroenterol Hepatol"},{"key":"1507_CR78","doi-asserted-by":"publisher","first-page":"e15551","DOI":"10.1111\/ped.15551","volume":"65","author":"E Miyata","year":"2023","unstructured":"Miyata E, Arai K, Takeuchi I, Shimizu H, Shimizu T. Refractory pediatric ulcerative colitis responding to high dose tofacitinib. Pediatr Int. 2023;65:e15551. https:\/\/doi.org\/10.1111\/ped.15551.","journal-title":"Pediatr Int"},{"key":"1507_CR79","unstructured":"FDA. FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions [Internet]. 09-01-2021. Available from: https:\/\/www.fda.gov\/drugs\/fda-drug-safety-podcasts\/fda-requires-warnings-about-increased-risk-serious-heart-related-eventscancer-blood-clots-and-death#:~:text=OnSeptember1%2C2021%2Cbased,medicinesXeljanzandXeljanzXR."},{"key":"1507_CR80","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s40264-016-0431-z","volume":"39","author":"MEB Clowse","year":"2016","unstructured":"Clowse MEB, Feldman SR, Isaacs JD, et al. Pregnancy outcomes in the tofacitinib safety databases for rheumatoid arthritis and psoriasis. Drug Saf. 2016;39:755\u201362.","journal-title":"Drug Saf"},{"key":"1507_CR81","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.1093\/ibd\/izy160","volume":"24","author":"U Mahadevan","year":"2018","unstructured":"Mahadevan U, Dubinsky MC, Su C, et al. Outcomes of pregnancies with maternal\/paternal exposure in the tofacitinib safety databases for ulcerative colitis. Inflamm Bowel Dis. 2018;24:2494\u2013500.","journal-title":"Inflamm Bowel Dis"},{"key":"1507_CR82","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1007\/s40265-020-01346-4","volume":"80","author":"JP Gisbert","year":"2020","unstructured":"Gisbert JP, Chaparro M. Safety of new biologics (vedolizumab and ustekinumab) and small molecules (tofacitinib) during pregnancy: a review. Drugs. 2020;80:1085\u2013100.","journal-title":"Drugs."},{"key":"1507_CR83","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00535-016-1283-0","volume":"52","author":"HC Chan","year":"2017","unstructured":"Chan HC, Ng SC. Emerging biologics in inflammatory bowel disease. J Gastroenterol. 2017;52:141\u201350. https:\/\/doi.org\/10.1007\/s00535-016-1283-0.","journal-title":"J Gastroenterol"},{"key":"1507_CR84","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1053\/j.gastro.2022.08.051","volume":"163","author":"M Balasubramaniam","year":"2022","unstructured":"Balasubramaniam M, Nandi N, Aswani-Omprakash T, et al. Identifying care challenges as opportunities for research and education in inflammatory bowel disease in South Asia. Clin Gastroenterol Hepatol. 2022;163:1145\u201350. https:\/\/doi.org\/10.1053\/j.gastro.2022.08.051.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1507_CR85","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1016\/j.cgh.2020.01.008","volume":"18","author":"S Singh","year":"2020","unstructured":"Singh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ. First- and second-line pharmacotherapies for patients with moderate to severely active ulcerative colitis: an Updated network meta-analysis. Clin Gastroenterol Hepatol. 2020;18:2179-91.e6. https:\/\/doi.org\/10.1016\/j.cgh.2020.01.008.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1507_CR86","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S2468-1253(21)00377-0","volume":"7","author":"JS Lasa","year":"2022","unstructured":"Lasa JS, Olivera PA, Danese S, Peyrin-Biroulet L. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2022;7:161\u201370.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1507_CR87","doi-asserted-by":"publisher","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","volume":"114","author":"DT Rubin","year":"2019","unstructured":"Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol. 2019;114:384\u2013413.","journal-title":"Am J Gastroenterol"},{"key":"1507_CR88","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","volume":"16","author":"T Raine","year":"2022","unstructured":"Raine T, Bonovas S, Burisch J, et al. ECCO Guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohns Colitis. 2022;16:2\u201317.","journal-title":"J Crohns Colitis"},{"key":"1507_CR89","doi-asserted-by":"publisher","unstructured":"Giri S, Bhrugumalla S, Kamuni A, et al. Upfront tofacitinib in patients with biological-na\u00efve ulcerative colitis \u2013 An Indian multicentric experience. Indian J Gastroenterol. 2023. https:\/\/doi.org\/10.1007\/s12664-023-01434-9.","DOI":"10.1007\/s12664-023-01434-9"},{"key":"1507_CR90","doi-asserted-by":"publisher","first-page":"i111","DOI":"10.1093\/ecco-jcc\/jjac190.0084","volume":"17 Supplement_1","author":"A Singh","year":"2023","unstructured":"Singh A, Midha V, Mahajan R, Kaur K, Singh D, Sood A. DOP44 Tofacitinib versus corticosteroids for induction of remission in moderately active ulcerative colitis (ORCHID): A prospective randomized open-label pilot study. J Crohns Colitis. 2023;17 Supplement_1:i111\u20132. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjac190.0084.","journal-title":"J Crohns Colitis"}],"container-title":["Indian Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12664-023-01507-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12664-023-01507-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12664-023-01507-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T03:38:19Z","timestamp":1710214699000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12664-023-01507-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":90,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["1507"],"URL":"https:\/\/doi.org\/10.1007\/s12664-023-01507-9","relation":{},"ISSN":["0254-8860","0975-0711"],"issn-type":[{"value":"0254-8860","type":"print"},{"value":"0975-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"13 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"RB, VS, RP, AJ, PP, NR, AK, AS, ASP, BG, DD, DM, GNR, GVR, KP, MP, MT, SB, SG, SuB, UCG, UD, VM, VGMP and\u00a0DNR declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors are solely responsible for the data and the\u00a0contents of the paper. In no way, the Honorary Editor-in-Chief,\u00a0Editorial Board Members, the Indian Society of Gastroenterology or the printer\/publishers are responsible for\u00a0the results\/findings and content of this article.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}